Virax Biolabs Group Limited (VRAX) Stock

Virax Biolabs Group Limited, based in London, United Kingdom, operates as a dynamic biotechnology company specializing in the sale, distribution, and marketing of diagnostic test kits, medical technology, and personal protective equipment (PPE) products. The company focuses on advancing solutions for the prevention, detection, diagnosis, and risk management of viral diseases within the realm of immunology. Under its ViraxClear brand, Virax Biolabs offers a comprehensive range of rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests, catering to diverse healthcare settings including clinics, pharmacies, laboratories, and hospitals across Europe, South America, the Asia Pacific, Sub-Saharan Africa, and beyond.

Beyond diagnostics, Virax Biolabs extends its product portfolio to include a variety of med-tech and PPE solutions under the ViraxCare brand. These products encompass essential employee protection equipment such as infrared thermometers, pulse oximeters, masks, gloves, and other critical PPE items. The company also distributes innovative nebulizing machines and smart wearable devices designed to support adherence to social distancing guidelines, thereby enhancing workplace safety and public health measures.

Operating an efficient online platform, Virax Biolabs Group Limited facilitates seamless access to its ViraxClear and ViraxCare products for corporate entities, individual consumers, hospital systems, and public and private institutions worldwide. Founded in 2021 and previously known as Virax Biolabs (Cayman) Limited, the company has rapidly emerged as a pivotal player in the global biotechnology landscape, leveraging cutting-edge technologies to meet evolving healthcare needs with reliable and accessible solutions.